News | March 28, 2026
Novartis acquires Excellergy to bolster allergy portfolio
The move leverages Novartis’ deep expertise in IgE biology and long-standing presence in allergic disease treatments
The move leverages Novartis’ deep expertise in IgE biology and long-standing presence in allergic disease treatments
Subscribe To Our Newsletter & Stay Updated